CIC/ATXN1-rearranged Tumors in the Central Nervous System Are Mainly Represented by Sarcomas: A Comprehensive Clinicopathological and Epigenetic Series

CIC fusions have been described in two different central nervous system (CNS) tumor entities. On one hand, fusions of CIC or ATXN1 genes belonging to the same complex of transcriptional repressors, were reported in the CIC-rearranged, sarcoma (SARC-CIC). The diagnosis of this tumor type, which was recently added to the World Health Organization (WHO) Classification of CNS tumors, is difficult mainly because the data concerning its histopathology (as compared to its soft tissue counterpart), immunoprofile, and clinical as well as radiological characteristics are scarce in the literature. On the other hand, a recent study, based on DNA-methylation profiling, has identified a novel high-grade neuroepithelial tumor characterized by recurrent CIC fusions (HGNET-CIC). The aim of this multicentric study was to characterize a cohort of 15 primary CNS tumors harboring a CIC or ATXN1 fusion in terms of clinical, radiological, histopathological, immunophenotypical, and epigenetic characteristics. According to the integrated diagnoses, 14/15 tumors corresponded to SARC-CIC, and only one to HGNET-CIC. The tumors showed similar clinical (mainly pediatric), radiological (mostly supratentorial, cystic, and contrast enhancing), immunophenotypical (common expression of glioneuronal markers), and genetic (similar spectrum of fusions) profiles but their histopathological appearance was clearly distinct. Moreover, we found a novel fusion transcript (CIC::EWSR1) in a SARC-CIC. Most DNA methylation profiles using the Heidelberg Brain Tumor Classifier (v12.8) annotated the samples to the methylation class "SARC-CIC" (9/14 tumors with available data). By using uniform manifold approximation and projection analysis, four other samples were classified as SARC-CIC and another clustered within the methylation class of HGNET-CIC. Our findings confirm that CNS CIC-fused tumors do not represent a single molecular tumor entity. Further analyses are needed to characterize HGNET-CIC in more detail. These results may help to refine the essential diagnostic criteria for SARC-CIC and their terminology (with a suggested consensual name of sarcoma, CIC/ATXN1-complex rearranged).

Citing Articles

CIC/ATXN1-rearranged tumors in the central nervous system are mainly represented by sarcomas: A comprehensive clinicopathological and epigenetic series.

Tauziede-Espariat A, Ebrahimi A, Boddaert N, Pietsch T, Grajkowska W, Blau T Brain Pathol. 2024; 35(2):e13303.

PMID: 39442927 PMC: 11835441. DOI: 10.1111/bpa.13303.

References

Sturm D, Orr B, Toprak U, Hovestadt V, Jones D, Capper D . New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell. 2016; 164(5):1060-1072. PMC: 5139621. DOI: 10.1016/j.cell.2016.01.015. View

Yoshida A, Wakai S, Ryo E, Miyata K, Miyazawa M, Yoshida K . Expanding the Phenotypic Spectrum of Mesenchymal Tumors Harboring the EWSR1-CREM Fusion. Am J Surg Pathol. 2019; 43(12):1622-1630. DOI: 10.1097/PAS.0000000000001331. View

Siegfried A, Masliah-Planchon J, Roux F, Larrieu-Ciron D, Pierron G, Nicaise Y . Brain tumor with an ATXN1-NUTM1 fusion gene expands the histologic spectrum of NUTM1-rearranged neoplasia. Acta Neuropathol Commun. 2020; 7(1):220. PMC: 6937844. DOI: 10.1186/s40478-019-0870-8. View

Song K, Huang Y, Xia C, Zhu H, Wang J . A case of CIC-rearranged sarcoma with CIC-LEUTX gene fusion in spinal cord. Neuropathology. 2022; 42(6):555-562. PMC: 10084232. DOI: 10.1111/neup.12850. View

Sparber-Sauer M, Corradini N, Affinita M, Milano G, Pierron G, Carton M . Clinical characteristics and outcomes for children, adolescents and young adults with "CIC-fused" or "BCOR-rearranged" soft tissue sarcomas: A multi-institutional European retrospective analysis. Cancer Med. 2023; 12(13):14346-14359. PMC: 10358194. DOI: 10.1002/cam4.6113. View

Capper D, Jones D, Sill M, Hovestadt V, Schrimpf D, Sturm D . DNA methylation-based classification of central nervous system tumours. Nature. 2018; 555(7697):469-474. PMC: 6093218. DOI: 10.1038/nature26000. View

Ouvrard C, Metais A, Brigot E, Berthaud C, Pucelle N, Lacombe J . ETV4 immunohistostaining is a sensitive and specific diagnostic biomarker for CIC-rearranged sarcoma of the central nervous system. Histopathology. 2022; 81(6):852-855. DOI: 10.1111/his.14796. View

Sugita S, Arai Y, Aoyama T, Asanuma H, Mukai W, Hama N . NUTM2A-CIC fusion small round cell sarcoma: a genetically distinct variant of CIC-rearranged sarcoma. Hum Pathol. 2017; 65:225-230. DOI: 10.1016/j.humpath.2017.01.012. View

Aranza S, Roydhouse C, Mitchell C, Vissers J, Lo W, Grimmond S . A rare diagnostically challenging case of CIC-DUX4 sarcoma arising in the neck. Pathology. 2022; 55(4):568-571. DOI: 10.1016/j.pathol.2022.03.010. View

10.

Tauziede-Espariat A, Siegfried A, Nicaise Y, Kergrohen T, Sievers P, Vasiljevic A . Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions. Acta Neuropathol Commun. 2021; 9(1):135. PMC: 8362233. DOI: 10.1186/s40478-021-01238-y. View

11.

Yamada S, Muto J, De Leon J, Kumai T, Ito K, Murayama K . Primary spinal intramedullary Ewing-like sarcoma harboring CIC-DUX4 translocation: a similar cytological appearance as its soft tissue counterpart but no lobulation in association with desmoplastic stroma. Brain Tumor Pathol. 2020; 37(3):111-117. DOI: 10.1007/s10014-020-00366-y. View

12.

Sievers P, Sill M, Schrimpf D, Abdullaev Z, Donson A, Lake J . Pediatric-type high-grade neuroepithelial tumors with CIC gene fusion share a common DNA methylation signature. NPJ Precis Oncol. 2023; 7(1):30. PMC: 10039012. DOI: 10.1038/s41698-023-00372-1. View

13.

Donahue J, Yakirevich E, Zhong S, Treaba D, Lakis N, Ali S . Primary Spinal Epidural CIC-DUX4 Undifferentiated Sarcoma in a Child. Pediatr Dev Pathol. 2017; 21(4):411-417. PMC: 5575979. DOI: 10.1177/1093526617707856. View

14.

Kallen M, Hornick J . The 2020 WHO Classification: What's New in Soft Tissue Tumor Pathology?. Am J Surg Pathol. 2020; 45(1):e1-e23. DOI: 10.1097/PAS.0000000000001552. View

15.

Antonescu C, Owosho A, Zhang L, Chen S, Deniz K, Huryn J . Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome: A Clinicopathologic and Molecular Study of 115 Cases. Am J Surg Pathol. 2017; 41(7):941-949. PMC: 5468475. DOI: 10.1097/PAS.0000000000000846. View

16.

Haidar A, Arekapudi S, DeMattia F, Abu-Isa E, Kraut M . High-grade undifferentiated small round cell sarcoma with t(4;19)(q35;q13.1) CIC-DUX4 fusion: emerging entities of soft tissue tumors with unique histopathologic features--a case report and literature review. Am J Case Rep. 2015; 16:87-94. PMC: 4338805. DOI: 10.12659/AJCR.892551. View

17.

Le Loarer F, Pissaloux D, Watson S, Godfraind C, Galmiche-Rolland L, Silva K . Clinicopathologic Features of CIC-NUTM1 Sarcomas, a New Molecular Variant of the Family of CIC-Fused Sarcomas. Am J Surg Pathol. 2018; 43(2):268-276. DOI: 10.1097/PAS.0000000000001187. View

18.

Pratt D, Kumar-Sinha C, Cieslik M, Mehra R, Xiao H, Shao L . A novel ATXN1-DUX4 fusion expands the spectrum of 'CIC-rearranged sarcoma' of the CNS to include non-CIC alterations. Acta Neuropathol. 2021; 141(4):619-622. DOI: 10.1007/s00401-021-02278-3. View

19.

Hu W, Wang J, Yuan L, Zhang X, Ji Y, Song C . Case Report: A Unique Case of Pediatric Central Nervous System Embryonal Tumor Harboring the - Fusion, Germline Variant and Somatic Mutation: Expanding the Spectrum of -Rearranged Neoplasia. Front Oncol. 2020; 10:598970. PMC: 7738346. DOI: 10.3389/fonc.2020.598970. View

20.

Tauziede-Espariat A, Ebrahimi A, Boddaert N, Pietsch T, Grajkowska W, Blau T . CIC/ATXN1-rearranged tumors in the central nervous system are mainly represented by sarcomas: A comprehensive clinicopathological and epigenetic series. Brain Pathol. 2024; 35(2):e13303. PMC: 11835441. DOI: 10.1111/bpa.13303. View